Option chain shows key data for Engie's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Engie.

Engie (OTC:ENGIY) Stock, Option Chain

Engie

Engie is a global energy firm formed by the 2008 merger of Gaz de France and Suez and the acquisition of International Power in 2012. It changed its name to Engie from GDF Suez in 2015. The company operates Europe's largest gas pipeline network in France and a global fleet of conventional and renewable power plants with 64 gigawatts of capacity on a consolidated basis. Engie also operates a diverse suite of other energy businesses.

Financial,Analyst,Using,Smartphone,With,Real-time,Stocks,,Commodities,And,Market

Equities

Fintech news covering the emerging Financial Technology services sector

Fintech

News

Health Care

Markets

Tech

AIQUY

ASML

AVGO

BIDU

ENGIY

WKCMY

In a recent report, global wealth manager UBS has identified the sectors that are likely to drive the next wave of technological innovation and the stocks that stand to benefit.

Which Stocks Will Dominate The Future Of Tech? UBS Shares Its Top Picks In AI, Healthtech, Greentech, And Fintech

Contracts

General

Packaging company WestRock Company (NYSE: WRK) said it has entered into 

Eco-Friendly Power Shift: Packaging Company WestRock Inks Renewable Energy Deal With ENGIE

Short Ideas

Trading Ideas

On Wednesday, shares of Engie (OTC: ENGIY) experienced volatile short activity. After the activity, the stock price went up +1.74% to $15.2.

The overall sentiment for ENGIY has been Bullish.

Short Volatility Alert: Engie

Engie SA

Wolfe Research analyst Akash Tewari initiates coverage on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform rating and announces Price Target of $95.

Price Target

Initiation

Analyst Ratings

BMRN

Wolfe Research Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating, Announces Price Target of $95

Wolfe Research analyst Alexandria Hammond initiates coverage on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Peer Perform rating.

BIIB

Wolfe Research Initiates Coverage On Biogen with Peer Perform Rating

Wolfe Research analyst Alexandria Hammond initiates coverage on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform rating and announces Price Target of $205.

ABBV

Wolfe Research Initiates Coverage On AbbVie with Outperform Rating, Announces Price Target of $205

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

Reiteration

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $23 price target.

CELC

Needham Reiterates Buy on Celcuity, Maintains $23 Price Target

Needham analyst Ryan Koontz reiterates Gilat Satellite Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) with a Buy and maintains $8.5 price target.

GILT

Needham Reiterates Buy on Gilat Satellite Networks, Maintains $8.5 Price Target

<ul>
<li>Aegon today announces a planned new EUR 150 million share buyback program, consistent with its policy to return excess Cash Capital at Holding to shareholders in the absence of value-creating opportunities. Barring unforeseen circumstances, the share buyback program will start at the beginning of January 2025 and is expected to be completed on or before June 30, 2025. The start of this share buyback program will be announced separately in due course.&nbsp;</li>
<li>The new planned EUR 150 million share buyback program will include an amount of about EUR 40 million to meet Aegon's obligations resulting from the share-based compensation plans for senior management. The repurchased shares resulting from these compensation plans will be held as treasury shares until they are allocated to the plan participants. Aegon intends to cancel the remainder of the repurchased shares resulting from the new planned share buyback program, subject to any relevant approval.</li>
</ul>

Aegon Announces €150M Share Buyback Starting January 2025, With €40M For Compensation And The Rest For Cancellation, Pending Approval

Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has filed a lawsuit against the Health Resources and Services Administration (HRSA). The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount offerings to hospitals.
What Happened: As per Eli Lilly&#8217;s official statement on Thursday, the conflict centers on the federal 340B program, which requires drug manufacturers to offer discounts to healthcare providers serving low-income communities. Participation in this program is crucial for drug companies to secure funding from government health insurance programs like Medicare and Medicaid.
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. However, HRSA, a division of the U.S. Health and Human Services Department, rejected this approach, stating it was inconsistent with the 340B law.
&#8220;HRSA does not have the authority to arbitrarily reject this model, which serves the original goals of the 340B program and improves transparency, efficiency, and program integrity,&#8221; the statement read.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Why It Matters: The lawsuit comes amid ongoing scrutiny of drug pricing practices. Recently, <a href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price">Doctors Without Borders</a> criticized Eli Lilly and other insulin manufacturers for maintaining high prices, urging them to provide affordable insulin to low- and middle-income countries.
This legal action also <a href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs">follows a similar lawsuit</a> by Johnson &amp; Johnson, which alleged the Health and Human Services Department of blocking its drug rebate plans. The 340B program has been subject to extensive legal challenges, with a U.S. appeals court previously allowing drugmakers to limit the use of outside pharmacies for dispensing under the program.
Meanwhile, Eli Lilly has been in the spotlight for its <a href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years">Phase 3 trial data</a> of tirzepatide, marketed as Mounjaro and Zepbound. The study showed promising results in reducing the risk of type 2 diabetes in patients with pre-diabetes and obesity, highlighting the company&#8217;s focus on innovative treatments.
Price Action: Eli Lilly was down by 0.28% during pre-market hours on Friday at the time of writing, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41921267/new-jersey-is-making-history-by-offering-medical-cannabis-as-employee-benefit?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">New Jersey Is Making History By Offering Medical Cannabis</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Biotech

Government

Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program

Needham analyst James Ricchiuti reiterates 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) with a Hold.

Needham Reiterates Hold on 3D Sys

Aegon trading update for third quarter 2024&nbsp;
• EUR 336 million operating capital generation, before holding funding and operating expenses. Full-year 2024 guidance raised to around EUR 1.2 billion, from around EUR 1.1 billion previously&nbsp;
• Capital ratios of the main units remain above their respective operating levels&nbsp;
• Planned new EUR 150 million share buyback program announced; completion expected in the first half of 2025. The program includes neutralization of shares issued for share-based compensation plans&nbsp;
• Cash Capital at Holding of EUR 1.5 billion as of September 30, 2024. Expect to reach mid-point of the target range (EUR 1.0 billion) by the end of 2026&nbsp;
• Completed program to purchase institutionally owned universal life policies. Terminated policies negatively impacted US RBC ratio by 16%-points. Expect 8%-points benefit in 4Q 2024 after equity funding repayment. Operating capital generation benefits from the program, as previously guided&nbsp;
• Strong commercial momentum in Asset Management and UK Workplace platform. US Strategic Assets experience c

Aegon Q3 Business Update: Operating Capital Generation €336M Before Holding Expenses; Raised FY24 Operating Capital Target To ~€1.2B, Up From The Previous Estimate Of €1.1B

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

GOVX

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Buy and maintains $9 price target.

INKT

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) with a Neutral.

STTK

HC Wainwright & Co. Reiterates Neutral on Shattuck Labs

Macro Economic Events

Econ #s

Economics

U.K. Labour Productivity For Q2 0.2% Vs. 0.1% Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $14 price target.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $14 Price Target

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-cola Europacific Partners Says The Financial Conduct Authority Approved Its Transfer Of Listing Category From Equity Shares Category To Equity Shares (Commercial Companies) Category Of Official List

Michael Burry, the hedge fund manager renowned for predicting the 2008 financial crisis, has significantly increased his exposure to Chinese technology companies while simultaneously implementing protective measures against potential downside risks, <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">according to regulatory filings</a>.
What Happened: Burry&#8217;s Scion Asset Management made several notable adjustments to its portfolio during the third quarter, with Chinese companies now representing its largest positions. The firm increased its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 29%, making it the fund&#8217;s largest holding valued at over $21 million as of September&#8217;s end.
In a similar move, Scion doubled its position in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), elevating it to the fund&#8217;s second-largest holding at approximately $20 million. The firm also expanded its stake in Chinese search giant Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) by 67%, bringing the position to $13.2 million.
However, in what appears to be a cautionary strategy, Burry has simultaneously established put options against these same holdings. Put options typically increase in value when the underlying securities decline, suggesting a hedging strategy designed to protect against potential market volatility.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41999238/ross-gerber-blasts-teslas-support-for-ending-ev-tax-credit-as-insanity-amid-reported-policy-shift-under-trump-administration">Long-Time Tesla Bull Rages As Elon Musk Reportedly Backs Trump&#8217;s Plan To Ax $7.5K EV Credit: &#8216;Insanity&#8217;</a>
The timing of these moves coincides with Beijing&#8217;s recent economic stimulus announcements aimed at reinvigorating growth in the world&#8217;s second-largest economy. While Chinese equities initially rallied in September following these signals, gains have moderated as investors await more concrete fiscal measures.
Beyond his Chinese technology focus, Burry has also increased positions in several U.S. companies, including Shift4 Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), American Coastal Insurance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>), and Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
Why It Matters: Burry&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">top three Chinese holdings</a> have posted average gains of nearly 60% over a two-month period, according to market data.
Burry&#8217;s moves are being closely watched by market participants, particularly given his track record. He gained widespread recognition for his prescient bet against mortgage-backed securities before the 2008 global financial crisis, a story later chronicled in Michael Lewis&#8216;s bestseller &#8220;The Big Short&#8221; and its subsequent Oscar-winning film adaptation.
It&#8217;s worth noting that these positions reflect holdings as of Sep. 30, as required by SEC regulations for funds managing over $100 million in assets. Given the 45-day reporting delay and Burry&#8217;s active trading style, current positions may have already changed.
The development comes as other <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">prominent investors adjust their Chinese holdings</a>. Billionaire investor David Tepper&#8217;s Appaloosa Management recently reduced its Alibaba stake by 5%, though the position remains the fund&#8217;s largest holding at 15.75% of its $6.7 billion portfolio.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">Jim Cramer Says These 10 &#8216;Frothy&#8217; Stocks Are Up Over 200% YTD, Including Rocket Lab, Palantir, And Carvana</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Global

ACIC

BABA

FOUR

'Big Short' Investor Michael Burry Doubles Down On Chinese Tech Stocks While Adding Protective Hedges

NATL

NCR Atleos Inks Five-year Agreement To Provide Atleos' Cashzone Network ATMs In The John Lewis Partnership's Waitrose Supermarkets Across The UK

Earnings

RLX Technology Q3 Adj EPADS $0.03, Sales $107.77M Beat $105.08M Estimate

Benchmark analyst Cody Acree maintains Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and raises the price target from $55 to $60.

TSEM

Benchmark Maintains Buy on Tower Semiconductor, Raises Price Target to $60

In a report released today, Wanda Serwinowska from UBS maintained a Buy rating on Engie SA (0LD0 – Research Report), with a price target of €17.50....

UBS Sticks to Their Buy Rating for Engie SA (0LD0)

Utility companies are positioned for long-term growth through clean energy investments as the world shifts towards renewable energy and infrastructure modernization. With rising demand, investors might consider stable utility stocks like Duke Energy (DUK), Engie (ENGIY), and Fortis (FTS), which offer high dividends. Read on... Utilities are experiencing rising demand from AI infrastructure, data centers, and EV charging, driving steady revenue growth. The sector also benefits from the shift to cleaner energy, which supports long-term growth potential. For investors seeking stability, utility stocks like Duke Energy Corporation (<a href="https://stocknews.com/stock/DUK/">DUK</a>), Engie SA (<a href="https://stocknews.com/stock/ENGIY/">ENGIY</a>), and Fortis Inc. (<a href="https://stocknews.com/stock/FTS/">FTS</a>) offer reliable dividends and promising dividend growth.
The utility sector is particularly promising and stable, supported by rising electricity demand from industrial growth and electric vehicles this year. Utilities play an essential role in sustaining critical tech sectors, providing steady demand and a defensive position against economic fluctuations. As a result, in the U.S., electricity demand is projected to grow by 3% in 2024 and by <a href="https://www.iea.org/reports/electricity-mid-year-update-july-2024/executive-summary">1.9% in 2025</a>.
As utilities transition from fossil fuels, they can achieve more stable costs and improved profitability by avoiding price volatility. Investments in nuclear, renewable energy, and methane reduction position utilities as leaders in clean, stable energy, while gas liquefaction supports the transition to lower-emission fuels. The global utilities market is projected to grow at <a href="https://www.researchandmarkets.com/report/utilities">6.8% annually</a>, reaching $8.31 trillion by 2027.
On top of it, anticipated interest rate cuts are likely to ease capital costs, benefiting utility companies reliant on substantial infrastructure spending. With promising local regulatory changes, the sector's outlook remains strong. Investors' interest in utility stocks is evident from the SPDR Select Sector Fund – Utilities' (<a href="https://stocknews.com/stock/XLU/">XLU</a>) 33.9% returns over the past year.
Considering these conducive trends, let's analyze the fundamental aspects of the three utility picks.
Duke Energy Corporation (<a href="https://stocknews.com/stock/DUK/">DUK</a>)
DUK and its subsidiaries operate as an energy company in the United States. It operates through two segments: Electric Utilities and Infrastructure (EU&amp;I), and Gas Utilities and Infrastructure (GU&amp;I).
On October 7, 2024, DUK declared a quarterly cash dividend of $1.05 per share on its common stock and $359.38 per share on its Series A preferred stock, both payable on December 16, 2024, to shareholders of record by November 15, 2024.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a>, DUK's 49.86% is 11.3% higher than the 44.79% industry average. Likewise, its 42.39% trailing-12-month Capex / Sales is 25.5% higher than the 33.77% industry average. Furthermore, the stock's 47.63% trailing-12-month EBITDA margin is 30.2% higher than the 36.58% industry average.
DUK has paid dividends for 17 consecutive years. Its annual dividend is $4.18, which translates to a yield of 3.63% at the current share price. Its four-year average dividend yield is 4.01%. Moreover, the company's dividend payouts have increased at a CAGR of 2% over the past three years.
DUK's total operating revenues for the second quarter that ended June 30, 2024, increased 9% year-over-year to $7.17 billion. Its operating income rose 19.4% over the year-ago value to $1.71 billion. Also, net earnings and adjusted EPS stood at $921 million and $1.18, reflecting increases of 29% and 29.7% year-over-year, respectively.
Street expects DUK's EPS for the quarter ending December 31, 2024, to increase 7.7% year-over-year to $1.63. Its revenue for the quarter ended September 30, 2024, is expected to grow 1.3% year-over-year to $8.10 billion. It surpassed the Street EPS estimates in three of the trailing four quarters.
Over the past year, the stock has gained 29.7% to close the last trading session at $115.27. Its 60-month beta is 0.46.
DUK's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
DUK is ranked #13 out of 59 stocks in the <a href="https://stocknews.com/category/utilities-domestic/">Utilities – Domestic</a> industry. It has a B grade for Growth, Momentum, and Stability. <a href="https://stocknews.com/stock/DUK/">Click here</a> to see DUK's ratings for Value, Sentiment, and Quality.
Engie SA (<a href="https://stocknews.com/stock/ENGIY/">ENGIY</a>)
Headquartered in Courbevoie, France, ENGIY operates in the power, natural gas, and energy services sectors. It functions through the Renewables, Networks, Energy Solutions, FlexGen, Retail, Nuclear, and Other segments.
On October 29, 2024, ENGIY and OCP Group announced a strategic partnership to accelerate OCP's energy transition in Morocco, focusing on renewable energy, energy storage, green hydrogen, and desalination.
The partnership includes developing four large-scale industrial projects and a research agenda, aiming to enhance competitiveness and support Morocco's ambitious energy goals.
On October 15, 2024, ENGIY announced the acquisition of its first biomethane production plant in Belgium, with a capacity of 68 GWh per year. This strategic purchase supports ENGIY's goal of producing 10 TWh of biomethane annually in Europe, enhancing its presence in the renewable energy sector.
In terms of the trailing-12-month Return on Total Capital, ENGIY's 6.82% is 69.8% higher than the 4.02% industry average. Likewise, its 15.94% trailing-12-month Return on Common Equity is 65.7% higher than the 9.62% industry average. Furthermore, the stock's 0.38x trailing-12-month asset turnover ratio is 75.2% higher than the 0.21x industry average.
ENGIY pays an annual dividend of $0.87, which translates to a yield of 5.15% at the current share price. Its four-year average dividend yield is 6.12%. Its dividend payouts have increased at a CAGR of 45.5% over the past three years.
For the first half ended June 30, 2024, ENGIY's revenues were €37.53 billion ($40.77 billion). Its cash flow from operating activities came in at €8.97 billion ($9.74 billion). Moreover, the company's net income and EPS were €2.40 billion ($2.61 billion) and €0.78, respectively, compared to a net loss of €217 million ($235.73 million) and a loss per share of $0.37.
For the quarter ended September 30, 2024, ENGIY's revenue is expected to increase marginally year-over-year to $16.15 billion. Over the past three months, the stock has gained 7.2% to close the last trading session at $16.84. Its 60-month beta is 0.94.
ENGIY's robust fundamentals are reflected in its POWR Ratings. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
ENGIY has an A grade for Growth and a B grade for Value, Momentum, Stability, and Sentiment. Within the B-rated <a href="https://stocknews.com/category/utilities-foreign/">Utilities – Foreign</a> industry, it is ranked #5 out of 51 stocks. To see ENGIY's rating for Quality, <a href="https://stocknews.com/stock/ENGIY/">click here</a>.
Fortis Inc. (<a href="https://stocknews.com/stock/FTS/">FTS</a>)
Headquartered in St. John's, Canada, FTS operates as an electric and gas utility company in Canada, the United States, and the Caribbean. It generates, transmits, and distributes electricity to southeastern Arizona and in Arizona's Mohave and Santa Cruz counties, with an aggregate capacity of 3,408 megawatts (MW), including 68 MW of solar capacity and 250 MW of wind capacity.
In terms of the trailing-12-month EBIT margin, FTS' 28.79% is 35.3% higher than the 21.28% industry average. Likewise, its 44.98% trailing-12-month EBITDA margin is 23% higher than the 36.58% industry average. Furthermore, the stock's 37.54% trailing-12-month Capex / Sales is 11.2% higher than the 33.77% industry average.
FTS' annualized dividend of $1.77 per share translates to a dividend yield of 4.09% on the current share price. Its four-year average yield is 3.85%. Over the past five years, FTS' dividend payments have grown at a CAGR of 5.1%. The company has paid dividends for the past eight years.
During the second quarter that ended June 30, 2024, adjusted net earnings increased 9.6% over the prior-year quarter to C$331 million ($237.8 million). Similarly, the company's adjusted net earnings per share came in at $0.67, up 8.1% from the year-ago value.
Analysts expect FTS' revenue for the quarter ended September 30, 2024, to increase 8.9% year-over-year to $2.13 billion. Its EPS for the quarter ending December 31, 2024, is expected to increase 11.7% year-over-year to $0.60. FTS surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past six months, the stock has gained 10% to close the last trading session at $43.23. Its 24-month beta is 0.37.
FTS' positive outlook is reflected in its POWR Ratings. It has a B grade for Momentum and Stability. It is ranked #43 in the Utilities - Foreign industry. <a href="https://stocknews.com/stock/FTS/">Click here</a> to see FTS' ratings for Growth, Value, Sentiment, and Quality.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
DUK shares were trading at $112.68 per share on Friday afternoon, down $2.59 (-2.25%). Year-to-date, DUK has gained 19.71%, versus a 21.27% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/duk-engiy-fts-3-utility-stocks-for-stability-and-dividend-growth/>3 Utility Stocks for Stability and Dividend Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Utility Stocks for Stability and Dividend Growth

Welcome to "StockTok," The Fly's weekly recap of Wall Street's reactions to social media stock news. ELECTION 2024: Trump Media (DJT) jumped as muc...

StockTok: Trump Media shares in focus following election win, M&A speculation

STMicroelectronics (STM) announced a 21-year power purchase agreement, or PPA, with BKH Solar Sdn Bhd, an entity jointly established by Engie Renew...

STMicroelectronics enters 21-year PPA with Engie SA entity and Conextone Energy

STMicroelectronics, ENGIE ink long-term energy supply deal

UBS analyst Wanda Serwinowska maintained a Buy rating on Engie SA (0LD0 – Research Report) today and set a price target of €17.50. The company's sh...

In a report released on November 7, Juan Rodriguez from Kepler Capital maintained a Buy rating on Engie SA (0LD0 – Research Report), with a price t...

Comments

Engie

Engie (ENGIY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga